RT Journal Article
SR Electronic
A1 Lederman, Lynne
T1 Development, Safety, and Efficacy of Janus Kinase Inhibitors in Rheumatoid Arthritis
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 18
SP 31
OP 32
DO 10.1177/155989771318015
UL http://mdc.sagepub.com/content/13/18/31.abstract
AB The four Janus kinases (JAKs), JAK1, JAK2, JAK3, and Tyk2, are essential components of the signaling pathway of certain cytokines [O'Shea JJ et al. N Engl J Med 2013]. This article reviews the role of JAKs in inflammation and JAK inhibitor efficacy and toxicity, the clinical data for tofacitinib, as well as discusses kinase inhibition in development, baricitinib, which strongly inhibits JAK1 and JAK2.